histologically proven prostate adenocarcinoma within 1 year of enrollment
Low risk: Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0
Intermediate risk:Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0
ECOG Performance Status 0-1
No prior prostate radiation or other definitive therapy

NCT01581749_inc_T1
Condition
prostate adenocarcinoma
NCT01581749_inc_T2
Qualifier
histologically proven
NCT01581749_inc_T3
Temporal
within 1 year of enrollment
NCT01581749_inc_T4
Reference_point
enrollment
NCT01581749_inc_T5
Measurement
Gleason
NCT01581749_inc_T6
Observation
Low risk
NCT01581749_inc_T7
Value
<or=6
NCT01581749_inc_T8
Measurement
PSA
NCT01581749_inc_T9
Value
<or=10
NCT01581749_inc_T10
Measurement
Clinical Stage
NCT01581749_inc_T12
Value
T1b-T2a
NCT01581749_inc_T13
Value
Mx
NCT01581749_inc_T14
Value
M0
NCT01581749_inc_T11
Value
Nx
NCT01581749_inc_T15
Value
N0
NCT01581749_inc_T16
Scope
T1b-T2a,Nx or N0, Mx or M0
NCT01581749_inc_T17
Scope
Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0
NCT01581749_inc_T18
Observation
Intermediate risk
NCT01581749_inc_T19
Measurement
Gleason
NCT01581749_inc_T20
Value
<or=6
NCT01581749_inc_T21
Measurement
PSA
NCT01581749_inc_T22
Value
<or=10
NCT01581749_inc_T23
Measurement
Clinical Stage
NCT01581749_inc_T24
Value
T2b
NCT01581749_inc_T25
Measurement
Gleason
NCT01581749_inc_T26
Value
=7
NCT01581749_inc_T27
Measurement
PSA
NCT01581749_inc_T28
Value
<or=10
NCT01581749_inc_T29
Measurement
Clinical Stage
NCT01581749_inc_T30
Value
T1b-T2b
NCT01581749_inc_T31
Measurement
Gleason
NCT01581749_inc_T32
Value
<or=6
NCT01581749_inc_T33
Measurement
PSA
NCT01581749_inc_T34
Value
> 10 & < or =20
NCT01581749_inc_T35
Measurement
Clinical Stage
NCT01581749_inc_T36
Value
T1b- T2b
NCT01581749_inc_T37
Value
Nx
NCT01581749_inc_T38
Value
NO
NCT01581749_inc_T39
Value
Mx
NCT01581749_inc_T40
Value
M0
NCT01581749_inc_T41
Scope
T1b- T2b, Nx or NO, Mx or M0
NCT01581749_inc_T42
Scope
Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0
NCT01581749_inc_T43
Scope
Gleason <or=6 & PSA<or=10 & Clinical Stage T2b
NCT01581749_inc_T44
Scope
Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b
NCT01581749_inc_T45
Scope
Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0
NCT01581749_inc_T46
Measurement
ECOG Performance Status
NCT01581749_inc_T47
Value
0-1
NCT01581749_inc_T48
Procedure
prostate radiation
NCT01581749_inc_T49
Negation
No
NCT01581749_inc_T50
Procedure
definitive therapy
NCT01581749_inc_T51
Scope
prostate radiation or other definitive therapy